CompletedNot Applicable

Reperfusion Syndrome and Vasoplegic Syndrome in Liver Transplant Surgery

Spain246 participantsStarted 2022-12-13

Plain-language summary

The incidence of postreperfusion syndrome (PRS) and vasoplegic syndrome (VS) is unknown, and occasionally can be confused since these syndromes share some hemodynamic characteristics. In these cases, monitoring with Swan Ganz catheter may be useful to make the differential diagnosis. The main outcome was to analyze reperfusion syndrome and vasoplegic syndrome in patients receiving vasoactive support during liver transplant surgery, in terms of incidence, risk factors and postoperative complications.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Consecutive patients ≥ 18 years-old, who underwent liver transplant surgery, monitored with Swan-Ganz catheter, with norepinephrine/adrenaline support during transplant surgery Exclusion Criteria: Acute liver failure, combined liver/kidney transplantation, re-transplantation, living-donor related transplantation, moderate to severe vascular and valvular heart disease, chronic kidney disease (serum creatinine \> 1.5), moderate and sever hepato-pulmonary syndrome, moderate and sever porto-pulmonary syndrome

What they're measuring

incidence of PRS and VS

Timeframe: in the first 5 min after vascular unclamping

Trial details

NCT IDNCT05658120

SponsorHospital Universitari Vall d'Hebron Research Institute

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-13

View on ClinicalTrials.gov More Postperfusion Syndrome trials